Sanofi's lixisenatide shows no CV benefit in ELIXA
This article was originally published in Scrip
Executive Summary
Sanofi's GLP-1 agonist lixisenatide has failed to show any benefit over placebo for cardiovascular safety in a high-risk population of adults with type 2 diabetes in the Phase IIIb ELIXA study.